SEARCH

SEARCH BY CITATION

References

  • 1
    Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004 Apr; 363(9418): 137785.
  • 2
    Martin E, Shapiro JR. Osteogenesis imperfecta:epidemiology and pathophysiology. Curr Osteoporos Rep. 2007 Sep; 5(3): 917.
  • 3
    Basel D, Steiner RD. Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition. Genet Med. 2009 Jun; 11(6): 37585.
  • 4
    Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R, LeMerrer M, Mortier G, Mundlos S, Nishimura G, Rimoin DL, Robertson S, Savarirayan R, Sillence D, Spranger J, Unger S, Zabel B, Superti-Furga A. Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet A. 2011 May; 155A(5): 94368.
  • 5
    Online Mendelian Inheritance in Man, Johns Hopkins University, Baltimore, Maryland. [cited 2011 Sep 25]. Available from: http://omim.org.
  • 6
    Becker J, Semler O, Gilissen C, Li Y, Bolz HJ, Giunta C, Bergmann C, Rohrbach M, Koerber F, Zimmermann K, de Vries P, Wirth B, Schoenau E, Wollnik B, Veltman JA, Hoischen A, Netzer C. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet. 2011 Mar 11; 88(3): 36271.
  • 7
    Homan EP, Rauch F, Grafe I, Lietman C, Doll JA, Dawson B, Bertin T, Napierala D, Morello R, Gibbs R, White L, Miki R, Cohn DH, Crawford S, Travers R, Glorieux FH, Lee B. Mutations in SERPINF1 cause osteogenesis imperfecta type VI. J Bone Miner Res. 2011; 26: 2798803.
  • 8
    Tombran-Tink J, Chader GG, Johnson LV. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res. 1991 Sep; 53(3): 4114.
  • 9
    Steele FR, Chader GJ, Johnson LV, Tombran-Tink J. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Nat Acad Sci USA. 1993; Feb 15; 90(4): 152630.
  • 10
    Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res. 2002 Jan; 17(1): 308.
  • 11
    Land C, Rauch F, Travers R, Glorieux FH. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone. 2007 Mar; 40(3): 63844.
  • 12
    Sillence DO, Rimoin DL. Classification of osteogenesis imperfect. Lancet. 1978 May 13; 1(8072): 10412.
  • 13
    Sillence DO, Rimoin DL, Danks DM. Clinical variability in osteogenesis imperfecta-variable expressivity or genetic heterogeneity. Birth Defects Orig Artic Ser. 1979; 15(5B): 11329.
  • 14
    Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979 Apr; 16(2): 10116.
  • 15
    Alanay Y, Avaygan H, Camacho N, Utine GE, Boduroglu K, Aktas D, Alikasifoglu M, Tuncbilek E, Orhan D, Bakar FT, Zabel B, Superti-Furga A, Bruckner-Tuderman L, Curry CJ, Pyott S, Byers PH, Eyre DR, Baldridge D, Lee B, Merrill AE, Davis EC, Cohn DH, Akarsu N, Krakow D. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am J Hum Genet. 2010 Apr 9; 86(4): 5519.
  • 16
    Shao H, Schvartz I, Shaltiel S. Secretion of pigment epithelium-derived factor: mutagenic study. Eur J Biochem. 2003 Mar; 270(5): 82231.
  • 17
    Doll JA, Stellmach VM, Bouck NP, Bergh AR, Lee C, Abramson LP, Cornwell ML, Pins MR, Borensztajn J, Crawford SE. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med. 2003 Jun; 9(6): 77480.
  • 18
    Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999 Jul 9; 285(5425): 2458.
  • 19
    Tombran-Tink J. PEDF in angiogenic eye diseases. Curr Mol Med. 2010 Apr; 10(3): 26778.
  • 20
    Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005 Dec 15; 438(7070): 96774.
  • 21
    Tombran-Tink J, Barnstable CJ. Osteoblasts and osteoclasts express PEDF, VEGF-A isoforms, and VEGF receptors: possible mediators of angiogenesis and matrix remodeling in the bone. Biochem Bioph Res Co. 2004 Apr 2; 316(2): 5739.
  • 22
    Quan GM, Ojaimi J, Li Y, Kartsogiannis V, Zhou H, Choong PF. Localization of pigment epithelium-derived factor in growing mouse bone. Calcif Tissue Int. 2005 Feb; 76(2): 14653.
  • 23
    Ek ET, Dass CR, Contreras KG, Choong PF. Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor. Clin Exp Metastasis. 2007; 24(2): 93106.
  • 24
    Akiyama T, Dass CR, Shinoda Y, Kawano H, Tanaka S, Choong PF. PEDF regulates osteoclasts via osteoprotegerin and RANKL. Biochem Bioph Res Co. 2010 Jan 1; 391(1): 78994.
  • 25
    Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 1999 Jun; 5(6): 6238.
  • 26
    Meyer C, Notari L, Becerra SP. Mapping the type I collagen-binding site on pigment epithelium-derived factor: implications for its antiangiogenic activity. J Biol Chem. 2002; Nov 22; 277(47): 454007.
  • 27
    Raghunath M, Bruckner P, Steinmann B. Delayed triple helix formation of mutant collagen from patients with osteogenesis imperfecta. J Mol Biol. 1994 Feb 25; 236(3): 9409.
  • 28
    Cabral WA, Chang W, Barnes AM, Weis M, Scott MA, Leikin S, Makareeva E, Kuznetsova NV, Rosenbaum KN, Tifft CJ, Bulas DI, Kozma C, Smith PA, Eyre DR, Marini JC. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet. 2007 Mar; 39(3): 35965.
  • 29
    Christiansen HE, Schwarze U, Pyott SM, AlSwaid A, Al Balwi M, Alrasheed S, Pepin MG, Weis MA, Eyre DR, Byers PH. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum Genet. 2010 Mar 12; 86(3): 38998.